Canada

  • Email
  • Help

The European Commission, the European Medicines Agency (EMA) and Health Canada have had confidentiality arrangements in place since 2007, allowing for the exchange of confidential information as part of their regulatory and scientific processes. The European union (EU) and Canada also have a mutual recognition agreement (MRA) in place on good manufacturing practice (GMP) compliance.

Within Health Canada, the Health Products and Food Branch deals with issues concerning EMA.

Confidentiality arrangement

EMA, the European Commission and Health Canada signed a confidentiality arrangement in 2007, which was renewed in 2013 for a further period of five years, with tacit renewal for subsequent five-year periods.

The confidential information that EMA and Health Canada can share includes:

Exchange of letters

Renewal of confidentiality arrangement 2013

Confidentiality arrangement 2007

Implementation 

The agencies have agreed an implementation plan which describes the processes each party will undertake to facilitate the sharing of information and documents:

MRA and collaboration on GMP compliance

The EU and Canada signed a MRA on GMP. This allows EU authorities and their Canadian counterparts to:

  • rely on each other's GMP inspections;
  • waive batch testing of products on entry into their territories;
  • share information on inspections and quality defects.

For more information on MRAs and the scope of the EU-Canada MRA, see Mutual recognition agreements.

EMA also participates in initiatives with partner authorities, including Health Canada, on GMP inspections which aim to better distribute inspections capacity, allowing more sites to be monitored and reducing unnecessary duplication. For more information, see International collaboration on GMP inspections.

Cluster activities

The agencies, together with other non-EU regulators, hold regular meetings by phone or videoconference in so-called ‘clusters’, which are areas of cooperation focusing on special topics and therapeutic areas identified as requiring an intensified exchange of information and collaboration.

For more information, see Cluster activities with regulatory partners.

Other areas of cooperation

Helath Canada and EMA have seconded liaison officials to each other’s premises on an ad hoc basis.

Following EMA’s implementation of the EU pharmacovigilance legislation, EMA and Health Canada strenghtened their cooperation on pharmacovigilance activities, including sharing advice on continuous improvement for business operations, development of performance indicators and methods for reporting on the impact of pharmacovigilance.

How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more

Related content

Related documents

External links